Travere Therapeutics shares are trading lower after the company announced a voluntary pause of enrollment in its Phase 3 HARMONY study of Pegtibatinase.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics shares declined following the company's decision to voluntarily pause enrollment in its Phase 3 HARMONY study of Pegtibatinase.
September 26, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Travere Therapeutics' stock is trading lower due to a voluntary pause in the enrollment of its Phase 3 HARMONY study of Pegtibatinase, which may raise concerns about the drug's development timeline.
The pause in the Phase 3 study is a significant event as it may indicate potential issues or delays in the drug's development, leading to investor concerns and a drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100